U.S., May 14 -- ClinicalTrials.gov registry received information related to the study (NCT06966830) titled 'Lacosamide Intravenous Injection for Emergency Termination of Status Epilepticus' on May 04.
Brief Summary: Status epilepticus (SE) is an acute and critical form of neurological and systemic diseases involving multiple clinical disciplines, with an annual incidence of (20-73) per 100,000 people and a clinical case fatality rate of 20%. Although there are many causes of SE, the primary goal of treatment is to terminate the seizures quickly, and timely and standardized treatment can reduce mortality and improve prognosis. The prognosis is closely related to the duration of the episode, and the longer the episode, the worse the prognosi...